BioSpace News Archive

SciSparc Ltd. announced that as part of its restructuring plans to unlock value for shareholders, it has appointed a new Vice President of Strategy and Business Development, Mr. Yaki Baranes, to structure business strategies and facilitate identifying new business opportunities.

Inhibrx, Inc. (Nasdaq: INBX) announced today that the U.S. Food and Drug Administration (FDA) granted Fast Track designation to INBRX-101, an optimized recombinant human AAT-Fc fusion protein, for the treatment of patients with emphysema due to alpha-1 antitrypsin deficiency (AATD).

Revamp Medical, Inc., a privately held clinical-stage medical technology company committed to developing solutions for Heart Failure congestion management, today announced closing of a Series A preferred stock financing led by KCK Medtech.

Stealth BioTherapeutics Inc. today announced their entry into an exclusive licensing agreement whereby Pharmanovia will commercialize elamipretide, Stealth’s lead investigational product candidate, in Europe and other key global territories for the treatment of Barth syndrome, an ultra-rare life-threatening cardiac condition caused by mitochondrial cardiolipin deficiency for which there are currently no approved treatments.

Know Labs, Inc. (NYSE American: KNW) today announced the results of a new study titled, “Algorithm Refinement in the Non-Invasive Detection of Blood Glucose Using Know Labs’ Bio-RFID Technology.”

Alpha Cognition Inc. announces a private placement offering of up to $6,500,000 of units at a price of $0.22 per unit.

Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced some of the latest data on the impact of comprehensive genomic profiling (CGP) for oncology patients, which will be presented at the American Society of Clinical Oncology’s Annual Meeting June 2–6 in Chicago.

9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today announced that the Board of Directors has accepted the resignation of John Temperato as President and Chief Executive Officer of the Company effective immediately.

ValGenesis, Inc. and Life Science Consulting Pvt. Ltd. have partnered to provide best-in-class digital validation solutions to enhance compliance and quality across life sciences disciplines such as production, quality control and assurance, information technology, and research and development.

DiaMedica Therapeutics Inc. today announced the appointment of Dr. Richard Kuntz to its Board of Directors effective May 30, 2023.